TABLE 1.

Demographic characteristics of all patients with typewriter tinnitus.

No.	Gender	Age (y)	Lateral	Possible Trigger	Symptom	Neurovascular Contact Type	Duration (y)	Pharmacological Treatment Scheme	Follow-up Time (mo)	Therapeutic Response	Relapse
1	F	56	L	/	TT+non-VP	I	0.2	Oxcarbazepine, 600 mg/d	16	CR	Relapse
2	F	43	L	/	TT	None	0.6	Oxcarbazepine, 600 mg/d	13	CR	No relapse
3	M	52	L	/	TT+VP	I	1.0	Oxcarbazepine, 600 mg/d	12	PR	No relapse
4	F	56	L	Neuromyelitis optica spectrum disorders	TT+VP	II	0.1	Oxcarbazepine, 600 mg/d	12	CR	Relapse
5	F	31	R	/	TT+VP	II	2.0	Oxcarbazepine, 600 mg/d	4	CR	No relapse
6	M	35	R	/	TT+VP	II	1.0	Oxcarbazepine, 600 mg/d	24	CR	No relapse
7	M	61	L	/	TT+VP	III	1.5	Carbamazepine, 800 mg/d	34	CR	Relapse
8	F	73	R	/	TT+VP	II	1.0	Oxcarbazepine, 600 mg/d	14	CR	Relapse
9	F	74	R	/	TT+VP	II	1.0	Carbamazepine, 400 mg/d	25	CR	Relapse
10	M	33	L	/	TT+VP	I	0.1	Oxcarbazepine, 600 mg/d	17	CR	No relapse
11	M	51	L	/	TT	I	0.6	Oxcarbazepine, 600 mg/d	7	CR	No relapse
12	M	44	R	/	TT	I	4.0	Oxcarbazepine, 600 mg/d	16	CR	Relapse
13	F	56	R	Ramsay Hunt Syndrome	TT+VP	I	0.4	Oxcarbazepine, 600 mg/d	6	CR	No relapse
14	F	65	R	/	TT	I	0.5	Carbamazepine, 400 mg/d	13	CR	No relapse
15	F	38	L	/	TT	I	0.8	Oxcarbazepine, 600 mg/d	6	CR	No relapse
16	F	37	R	/	TT	None	0.1	Oxcarbazepine, 600 mg/d, and carbamazepine, 400 mg/d	6	NR	/
17	F	33	R	/	TT+ VP	II	3.0	Oxcarbazepine, 600 mg/d	14	CR	No relapse
18	M	52	R	/	TT+VP	I	0.3	Oxcarbazepine, 600 mg/d	6	CR	Relapse

CR = complete remission; F = female; ; L = left; M = male; PR = partial remission; R = right; TT = typewriter tinnitus; VP = vestibular paroxysmia.

published online ahead of print May 11, 2023.